Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589789 | 0.93 | PTGER1 (0.45) | PTGER1SMN1; SMN2POLBMEN1ALDH1A1 | |
| SCHEMBL592168 | 0.89 | PTGER1 (0.43) | PTGER1SMN1; SMN2POLBMEN1ALDH1A1 | |
| SCHEMBL4261198 | 0.83 | PTGER1 (0.42) | PTGER1SMN1; SMN2POLBMEN1ALDH1A1 | |
| SCHEMBL423612 | 0.80 | SLC16A3 (0.43) | SMN1; SMN2POLBALDH1A1LMNAMAPT | |
| SCHEMBL24621637 | 0.78 | POLB (0.44) | SMN1; SMN2POLBMEN1ALDH1A1LMNA | |
| SCHEMBL958268 | 0.76 | MALT1 (0.40) | SMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL29558300 | 0.76 | MALT1 (0.40) | SMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL589486 | 0.76 | POLB (0.49) | POLBMEN1LMNAMAPTKMT2A | |
| SCHEMBL4759799 | 0.76 | SMN1; SMN2 (0.56) | PTGER1SMN1; SMN2POLBALDH1A1MGLL | |
| SCHEMBL950705 | 0.74 | MALT1 (0.38) | SMN1; SMN2POLBMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2093223-B1 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-8115006-B2 | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA ,LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2093223-A1 | PROCESS FOR PRODUCTION OF ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | NAAA, AAAS, AADAC | PTGER1 4293/4885SMN1; SMN2 4856/4885POLB 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.